Peripheral Arterial Disease: A Review of Disease Awareness and Management

https://doi.org/10.1016/j.amjopharm.2006.12.006Get rights and content

Abstract

Background:

Peripheral arterial disease (PAD) is a progressive atherosclerotic condition affecting ≈27 million people in North America and Europe. Albeit a common clinical malady, it is underrecognized and undertreated.

Objective:

The goal of this article was to review the pathophysiology, clinical implications, diagnosis, and management of PAD.

Methods:

Relevant published information was identified through a search of MEDLINE (1966–2006). Search terms used included peripheral vascular diseases, intermittent claudication, arterial occlusive diseases, antiplatelet therapy, HMG-CoA reductase inhibitors, risk factors, smoking cessation, adrenergic beta-antagonists, and angiotensin-converting enzymes.

Results:

PAD is associated with an increased risk of cardiovascular and cerebrovascular disease as well as a reduction in quality of life. PAD symptoms are not always present with the disease; therefore, improvements in screening methods for at-risk patients are necessary. Patients at risk for PAD should be routinely screened, and appropriate management—including antiplatelet therapy and risk factor modifications—should be initiated once the disease is recognized. Risk factor modifications should include smoking cessation as well as blood pressure and cholesterol management. Acetylsalicylic acid (ASA) is the antiplatelet of choice, and clopidogrel should be used as an alternative if ASA therapy is contraindicated or an intolerance is present. Cilostazol has a minimal role for the symptomatic relief in patients with disabling intermittent claudication. All patients with PAD should be treated with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor and potentially an angiotensin-converting enzyme inhibitor. R-Blockers should not be avoided unless documented worsening of symptoms is associated with their use.

Conclusions:

Patients at risk for PAD should be routinely screened, and appropriate management including antiplatelet therapy and risk factor modifications should be initiated once the disease is recognized.

References (98)

  • WilligendaelE.M. et al.

    Influence of smoking on incidence and prevalence of peripheral arterial disease

    J Vase Surg.

    (2004)
  • WolfP.A. et al.

    Cigarette smoking as a risk factor for stroke. The Framingham Study

    JAMA

    (1988)
  • SmithR.S. et al.

    Effect of beta-blocking drugs on peripheral blood flow in intermittent claudication

    J Cardiorasc Pbarmacol.

    (1982)
  • UbbinkD.T. et al.

    Effect of beta-blockers on peripheral skin microcirculation in hypertension and peripheral vascular disease

    J Vasc Surg.

    (2003)
  • CosmiB. et al.

    Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication (Cochrane Review)

    Cochrane Database Syst Rev.

    (2001)
  • MohlerE.R. et al.

    Treatment of intermittent claudication with beraprost sodium, an orally active prostaglandin 12 analogue: A double-bfinded, randomized, controlled trial

    J Am Coll Cardiol.

    (2003)
  • BalsanoF. et al.

    Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study

    Circulation

    (1993)
  • Clinical Trials: US National Institutes of Health. 040143; 04-H-0143; EW-A-401 to Treat Intermittent Claudication....
  • BelchJ.J. et al.

    Prevention of Atherothrombotic Disease Network. Critical issues in peripheral arterial disease detection and management: A call to action

    Arch Intern Med.

    (2003)
  • CriquiM.H. et al.

    The prevalence of peripheral arterial disease in a defined population

    Circulation

    (1985)
  • FaxonD.P. et al.

    American Heart Association. Atherosclerotic Vascular Disease Conference: Executive summary: Atherosclerotic Vascular Disease Conference proceeding for healthcare professionals from a special writing group of the American Heart Association

    Circulation

    (2004)
  • LibbyP.

    Inflammation in atherosclerosis

    Nature

    (2002)
  • FaxonD.P. et al.

    Atherosclerotic Vascular Disease Conference: Writing Group III: Pathophysiology

    Circulation

    (2004)
  • MoncadaS. et al.

    The L-arginine-nitric oxide pathway

    N Engl J Med.

    (1993)
  • ForstermannU.

    Properties and mechanisms of production and action of endothelium-derived relaxing factor

    J Cardiovasc Pharmacol.

    (1986)
  • LoscalzoJ.

    Nitric oxide insufficiency, platelet activation, and arterial thrombosis

    Circ Res.

    (2001)
  • StockerR. et al.

    Role of oxidative modifications in atherosclerosis

    Physiol Rev.

    (2004)
  • RosenfieldK. et al.

    Disease of peripheral vessels

  • CriquiM.H.

    Peripheral arterial disease—epidemiological aspects

    Vase Med.

    (2001)
  • GreenlandP.

    Clinical significance, detection and medical treatment for peripheral arterial disease

    J Cardiopulrn Rebabil.

    (2002)
  • CriquiM.H. et al.

    Mortality over a period of 10 years in patients with peripheral arterial disease

    N Engl J Med.

    (1992)
  • NewmanA.B.

    Peripheral arterial disease: Insights from population studies of older adults

    J Am Geriatr Soc.

    (2000)
  • HirschA.T. et al.

    Peripheral arterial disease detection, awareness, and treatment in primary care

    JAMA

    (2001)
  • McDermottM.M. et al.

    Prevalence and significance of unrecognized lower extremity peripheral arterial disease in general medicine practice

    J Gen Intern Med.

    (2001)
  • McDermottM.M. et al.

    The ankle brachial index is associated with leg function and physical activity: The Walking and Leg Circulation Study

    Ann Intern Med.

    (2002)
  • CriquiM.H. et al.

    The correlation between symptoms and non-invasive test results in patients referred for peripheral arterial disease testing

    Vase Med.

    (1996)
  • MurabitoJ.M. et al.

    The anklebrachial index in the elderly and risk of stroke, coronary disease, and death: The Framingham Study

    Arch Intern Med.

    (2003)
  • ResnickH.E. et al.

    Relationship of high and low ankle brachial index to allcause and cardiovascular disease mortality: The Strong Heart Study

    Circulation

    (2004)
  • HirschA.T. et al.

    ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery

  • American Diabetes Association

    Peripheral arterial disease in people with diabetes

    Diabetes Care.

    (2003)
  • McDermottM.M. et al.

    Exertional leg symptoms other than intermittent claudication are common in peripheral arterial disease

    Arch Intern Med.

    (1999)
  • Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

    BMJ

    (2002)
  • The CAPRIE Steering Committee

    A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)

    Lancet

    (1996)
  • CioconJ.O. et al.

    A comparison between aspirin and pentoxifylline in relieving claudication due to peripheral vascular disease in the elderly

    Angiology

    (1997)
  • BaumgartnerI. et al.

    Double-blind study of the effect of dipyridamole in patients with intermittent claudication [in German]

    Vasa

    (1992)
  • RankeC. et al.

    Controlled trial of high- versus low-dose aspirin treatment after percutaneous transluminal angioplasty in patients with peripheral vascular disease

    Clin Inroestig

    (1994)
  • JanzonL. et al.

    Prevention of myocardial infarction and stroke in patients with intermittent claudication: Effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study

    J Intern Med.

    (1990)
  • ArcanJ.C. et al.

    Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications

    Angiology

    (1988)
  • BoisselJ.P. et al.

    Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs?

    Thromb Haemost

    (1989)
  • Cited by (32)

    • Effects of intermittent claudication due to arterial disease on pain-free gait

      2021, Clinical Biomechanics
      Citation Excerpt :

      Peripheral arterial disease affects 202 million people worldwide (Song et al., 2019); 20 million people in Europe, 8–10 million in north America, 10% of individuals over 65 years of age and 20% of those over 80 (Watson et al., 2006).

    • Peripheral Arterial Disease

      2018, Heart Lung and Circulation
    • Treatment of Superficial Femoral Artery Restenosis

      2017, Journal of Vascular and Interventional Radiology
    • COPART Risk Score Predicts Long-term Mortality in Peripheral Arterial Occlusive Disease

      2015, European Journal of Vascular and Endovascular Surgery
      Citation Excerpt :

      Supervised exercise could also achieve a further reduction of mortality, particularly in the HR group, as claudicants would be the ideal cohort for this type of therapy.26 Providing the calculated prognosis in the discharge letter after the first endovascular recanalization might help to minimise poor management of CV risk factors in PAOD patients by primary care physicians.27–30 Furthermore, closer control of coexistent CAD or cerebrovascular disease would help to achieve a reduction of mortality.

    View all citing articles on Scopus
    View full text